Management of hypertension in non-dialysis and dialysis patients with chronic kidney disease: Chinese expert consensus.
10.3760/cma.j.cn112138-20220909-00670
- Collective Name:Consensus Expert Panel on the Management of Hypertension in Chronic Kidney Disease
- Publication Type:Journal Article
- MeSH:
Humans;
Cardiovascular Diseases;
Consensus;
East Asian People;
Hypertension/therapy*;
Renal Insufficiency, Chronic/therapy*;
Renal Dialysis
- From:
Chinese Journal of Internal Medicine
2023;62(7):748-774
- CountryChina
- Language:Chinese
-
Abstract:
Chronic kidney disease (CKD) is a global public health problem that is usually progressive. Hypertension is a risk factor for the progression of CKD, and cardiovascular disease is the most common cause of death in patients with CKD. In Chinese patients with CKD, there is a high prevalence of hypertension and a poor rate of control. Several studies have demonstrated that effective blood pressure control can delay the progression of kidney disease and reduce the risk of cardiovascular events and all-cause mortality. Based on previously published high-quality evidence, guidelines and consensus reports, the Zhongguancun Nephropathy and Blood Purification Innovation Alliance formulated a new consensus. This consensus includes blood pressure measurement; the blood pressure management of non-dialysis patients, dialysis patients and kidney transplantation patients, and the interaction between commonly used drugs and antihypertensive drugs. The consensus aims to further strengthen the standardization and safety of blood pressure management in CKD patients, delay disease progression, reduce disease burden, and comprehensively improve the quality-of-life and prognosis of patients with CKD.
